SecBot SecBot
425 ·Filed Jul 20, 2026

TEM

Tempus AI, Inc.
BULLISH
Impact 7/10
Horizonmonths Processed3mo ago SEC0001193125-26-309090
Actionable Insight ▲ Bullish

Monitor for Personalis shareholder vote and HSR regulatory clearance as key milestones toward Q4 2026 close. The stock-for-stock structure means TEM's stock price at closing will determine the final exchange ratio; a decline below $46.00 gives Personalis the right to terminate. Watch for any competing bids or activist interest given the modest 6% premium to Personalis's closing price.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$48.98
T+0 close · Jul 20, 2026 · via day close
Latest settled
+39.28%
T+60 · $68.22
Vs SPY
+35.31%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 21 $48.98entry
  2. T+1 · 4mo ago −4.12%α −4.01% · $46.96
  3. T+5 · 4mo ago −12.39%α −11.16% · $42.91
  4. T+20 · 3mo ago +0.78%α −1.79% · $49.36
  5. T+60 · 5w ago +39.28%α +35.31% · $68.22
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Tempus AI (TEM) filed an investor presentation deck as a Rule 425 communication, reinforcing its July 20, 2026 announcement to acquire Personalis (PSNL) for $16.25/share in a stock-for-stock transaction valued at $1.7Bn ($1.5Bn net of Tempus's existing stake). The presentation emphasizes the strategic rationale of integrating Personalis's ultrasensitive MRD technology into Tempus's AI-enabled precision oncology platform, targeting a >$20B market opportunity, and highlights Personalis's Q2 test volume of 10,384 (33% sequential growth) and >35,000 total tests delivered. The deal is expected to close in Q4 2026, subject to Personalis shareholder approval and regulatory clearances.

Key Financial Metrics

Deal Value
$1.7B
Premium
6%
Deal Type
acquisition

Key Facts

  • Total transaction value of $1.7Bn ($1.5Bn net of Tempus's existing ownership interest)
  • Personalis shareholders to receive $16.25 per share in a combination of Tempus stock and up to 50% cash at Tempus's discretion
  • Floating exchange ratio with a maximum of 0.3356x Tempus Class A common stock per Personalis share
  • Closing expected in Q4 2026 at earliest, subject to Personalis shareholder approval and regulatory clearances (including HSR)
  • Personalis has delivered >35,000 tests to date, with Q2 sequential test volume growth of 33% (10,384 tests in Q2)
  • Only ~10% of Tempus's sales force currently sells NeXT Personal Dx, implying significant volume acceleration potential
  • Tempus's infrastructure includes ~65% of U.S. academic medical centers and >55% of oncologists connected, with ~1M NGS tests run annually across 4 labs

Financial Impact

Acquisition valued at $1.7Bn total ($1.5Bn net of existing stake), representing ~18% of Tempus's $9.4B market cap. The deal expands Tempus into a >$20B MRD market and is expected to drive meaningful revenue growth through full ownership of Personalis's test portfolio and commercial infrastructure.

revenuemarket sharetest volume

Risk Factors

  • Integration risk combining two platforms and sales forces
  • Regulatory approval delays or conditions (HSR clearance)
  • Personalis shareholder approval not obtained
  • Termination risk if Tempus stock falls below $46.00 prior to closing
  • Potential litigation challenging the transaction

Market Snapshot

Exchange
Nasdaq
Sector
Services-Computer Programming, Data Processing, Etc.
Analyst Consensus
63% bullish (24 analysts)

Investment Themes

Software & IT

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
425 Filing (TEM), Batch item 10001193125-26-309090
Document: 0001193125-26-309090-index-headers.html0001193125-26-309090
Document: 0001193125-26-309090-index.html0001193125-26-309090
Document: 0001193125-26-309090.txt0001193125-26-309090
425 Filing (TEM), Batch item 50001193125-26-309090

Track record

45 reports on TEM

Performance horizon

7 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +53.09% at T+60 after the Jul 30, 2026 report. 16 of 17 went positive at some point.

Filters
  1. Nov 9, 20267d ago Press Release Neutral 3/10 Entry $80.54 Now $64.76 −19.59% settles Feb 8
  2. Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $76.05 Now $64.76 −14.85% settles Feb 4
  3. Nov 4, 202612d ago Insider Cluster Neutral 3/10 Entry $70.43 Now $64.76 −8.05% settles Feb 3
  4. Nov 2, 202614d ago 144 Neutral 1/10 Entry $77.80 Now $64.76 −16.76% settles Feb 1
  5. Nov 2, 202614d ago 8-K Bullish 6/10 Entry $78.48 Now $64.76 −17.48% settles Jan 29
  6. Oct 28, 202619d ago SC 13G/A Neutral 2/10 Entry $77.84 Now $64.76 −16.80% settles Jan 27
  7. Oct 28, 202619d ago Institutional Cluster Neutral 3/10 Entry $76.61 Now $64.76 −15.47% settles Jan 26
  8. Oct 27, 202620d ago 144 Neutral 3/10 Entry $76.61 Now $64.76 −15.47% settles Jan 26
  9. Oct 23, 202624d ago 8-K Bullish 6/10 Entry $67.62 Now $64.76 −4.22% settles Jan 21
  10. Oct 22, 202626d ago EFFECT Neutral 4/10 Entry $63.81 Now $64.76 +1.49% settles Jan 20
Showing 10 of 45

US Market Status

Market Closed · Opens in 9h 3m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 20, 2026